Manav V Vyas1, Pranali K Raval2, Jennifer A Watt3, David F Tang-Wai4. 1. Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada. Electronic address: manav.vyas@mail.utoronto.ca. 2. Health Sciences Program, McMaster University, Hamilton, Ontario, Canada. 3. Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; Division of Geriatric Medicine, Department of Medicine, University of Toronto, Toronto, Ontario, Canada. 4. Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Division of Geriatric Medicine, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Abstract
BACKGROUND: Despite the projected increase in dementia cases affecting various ethnic groups worldwide, representation of these ethnic groups in randomized controlled trials (RCTs) of treatments to improve cognitive function in persons with dementia or mild cognitive impairment (MCI) is unclear. We aimed to quantify the inclusion of various ethnicities in dementia treatment RCTs. METHODS: RCTs published between January 1, 2000 and August 1, 2017 (inclusive) were included. Participants were community-dwelling adults with a diagnosis of either dementia or MCI randomized to receive either pharmacological or non-pharmacological interventions to improve cognitive function. Analyses were performed to determine study-level characteristics associated with recruitment of various ethnic groups. Random effects meta-analyses were conducted to determine the pooled prevalence for each ethnicity. RESULTS: A total of 96 RCTs consisting of 37,278 participants (57.2% female) were included in the final analysis. Only 39 (39.4%) trials reported the ethnicity of included participants. The pooled proportion of non-Caucasian trial participants was 11.4% (95% CI, 7.5 to 15.9%). Meta-regression results showed that there has been a slow increase in representation of non-Caucasian ethnic groups over time (0.6% per year, P value = 0.041). CONCLUSIONS: There is an underreporting of the ethnicity of trial participants and underrepresentation of non-Caucasian ethnic groups in RCTs designed to improve cognitive function in persons with dementia or MCI.
BACKGROUND: Despite the projected increase in dementia cases affecting various ethnic groups worldwide, representation of these ethnic groups in randomized controlled trials (RCTs) of treatments to improve cognitive function in persons with dementia or mild cognitive impairment (MCI) is unclear. We aimed to quantify the inclusion of various ethnicities in dementia treatment RCTs. METHODS: RCTs published between January 1, 2000 and August 1, 2017 (inclusive) were included. Participants were community-dwelling adults with a diagnosis of either dementia or MCI randomized to receive either pharmacological or non-pharmacological interventions to improve cognitive function. Analyses were performed to determine study-level characteristics associated with recruitment of various ethnic groups. Random effects meta-analyses were conducted to determine the pooled prevalence for each ethnicity. RESULTS: A total of 96 RCTs consisting of 37,278 participants (57.2% female) were included in the final analysis. Only 39 (39.4%) trials reported the ethnicity of included participants. The pooled proportion of non-Caucasian trial participants was 11.4% (95% CI, 7.5 to 15.9%). Meta-regression results showed that there has been a slow increase in representation of non-Caucasian ethnic groups over time (0.6% per year, P value = 0.041). CONCLUSIONS: There is an underreporting of the ethnicity of trial participants and underrepresentation of non-Caucasian ethnic groups in RCTs designed to improve cognitive function in persons with dementia or MCI.
Authors: Miriam T Ashford; Rema Raman; Garrett Miller; Michael C Donohue; Ozioma C Okonkwo; Monica Rivera Mindt; Rachel L Nosheny; Godfrey A Coker; Ronald C Petersen; Paul S Aisen; Michael W Weiner Journal: Alzheimers Dement Date: 2022-02-25 Impact factor: 16.655
Authors: Phazha L K Bothongo; Mark Jitlal; Eve Parry; Sheena Waters; Isabelle F Foote; Cameron J Watson; Jack Cuzick; Gavin Giovannoni; Ruth Dobson; Alastair J Noyce; Naaheed Mukadam; Jonathan P Bestwick; Charles R Marshall Journal: Lancet Reg Health Eur Date: 2022-02-11
Authors: María P Aranda; Ian N Kremer; Ladson Hinton; Julie Zissimopoulos; Rachel A Whitmer; Cynthia Huling Hummel; Laura Trejo; Chanee Fabius Journal: J Am Geriatr Soc Date: 2021-07 Impact factor: 7.538
Authors: Eric D Vidoni; Amanda Szabo-Reed; Chaeryon Kang; Ashley R Shaw; Jaime Perales-Puchalt; George Grove; Morgan Hamill; Donovan Henry; Jeffrey M Burns; Charles Hillman; Arthur F Kramer; Edward McAuley; Kirk I Erickson Journal: Contemp Clin Trials Commun Date: 2020-10-09